BioCentury
ARTICLE | Clinical News

Keryx jumps on Zerenex data in non-dialysis CKD patients

November 6, 2013 1:50 AM UTC

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) jumped $2.08 (19%) to $13.18 on Tuesday after reporting that Zerenex ferric citrate met the co-primary endpoints in a Phase II trial to treat hyperphosphatemia in non-dialysis dependent patients with chronic kidney disease (CKD). Zerenex improved mean serum phosphorus and transferrin saturation levels from baseline to week 12 vs. placebo (p<0.001 for both endpoints). The double-blind, U.S. trial enrolled 141 anemic patients with stage III-V non-dialysis dependent CKD and baseline serum phosphorus levels of 4 mg/dL or greater. ...